Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2020. The report serves as a transaction notification regarding a purchase of ordinary shares by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Purchase of Ordinary Shares |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Volume | 11,730 shares |
| Price | £17.05 per share |
| Transaction Date | February 06, 2020 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position or operations. It discloses a single transaction executed by Sir Jonathan Symonds, the Non-Executive Chairman.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory notification of insider trading activity.
Key Facts for Investor Verification
- Insider Activity: Sir Jonathan Symonds (Non-Executive Chairman) purchased 11,730 shares.
- Transaction Value: The purchase was made at £17.05 per share on the London Stock Exchange.
- Reporting Nature: This is a mandatory disclosure of a PDMR transaction, not a financial results report.
- Missing Data: The filing text does not provide a clear value for company-wide revenue, earnings, or cash flow.